Cowen & Co. Sticks to Its Hold Rating for GlaxoSmithKline

By Austin Angelo

Cowen & Co. analyst Steve Scala reiterated a Hold rating on GlaxoSmithKline (NYSE: GSK) yesterday and set a price target of $40. The company’s shares opened today at $37.21.

According to, Scala is a 3-star analyst with an average return of 5.7% and a 56.7% success rate. Scala covers the Healthcare sector, focusing on stocks such as Sanofi-Aventis Sa, Nexvet Biopharma, and Merck & Company.

GlaxoSmithKline has an analyst consensus of Strong Buy, with a price target consensus of $40.

GlaxoSmithKline’s market cap is currently $90.04B and has a P/E ratio of 46.77. The company has a book value ratio of -978.7347.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

‘GlaxoSmithKline Plc is a global healthcare company which engages in developing, manufacturing, and marketing of pharmaceutical products including vaccines, over the counter medicines and health-related consumer products. It operates through the following segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.